Error loading player: No playable sources found
2080
IBD Diagnosis. Monitoring, and Prediction of Complications
Date
May 18, 2024
SOCIETY: AGA This session highlights the latest research on novel prediction models in IBD as well as the role of the fecal microbiome and imaging in IBD.
Presentations:
| DEVELOPMENT AND VALIDATION OF AN INTEGRATED RISK SCORE FOR PREDICTING FUTURE RISK OF CROHN'S DISEASE UP TO 7 YEARS BEFORE DIAGNOSIS IN HEALTHY FIRST-DEGREE RELATIVES: THE CCC-GEM PROJECT, A MULTICENTRE PROSPECTIVE COHORT STUDY |
| FAECAL MICROBIOME AS TARGETED NON-INVASIVE BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE: A CROSS-POPULATION METAGENOMIC ANALYSIS IN SIX COHORTS |
| COMPARISON OF DIAGNOSTIC ACCURACY BETWEEN CROSS SECTIONAL IMAGING TECHNIQUES AND SMALL INTESTINAL CONTRAST ULTRASONOGRAPHY IN SMALL BOWEL CROHN’S DISEASE (THE CACTUS-CD TRIAL) : A PAIRED VALIDATING CONFIRMATORY STUDY |
| EARLY INTESTINAL ULTRASOUND RESPONSE TO BIOLOGIC AND SMALL MOLECULE THERAPY PREDICTS ENDOSCOPIC OUTCOMES IN CHILDREN WITH ULCERATIVE COLITIS |
| A CLINICAL SCORE FOR UC2CD, A NOVEL SUBGROUP IN INFLAMMATORY BOWEL DISEASES (IBD) WITH DISTINCT SEROLOGICAL, GENETIC AND CLINICAL FEATURES |
| SIMPLE ENDOSCOPIC SCORE FOR CROHN’S DISEASE (SES-CD) ≥ 7 PREDICTS DISEASE PROGRESSION IN PATIENTS WITH MILD CD |
Moderators
University of California San Francisco
Universite de Montreal
Speakers
Icahn School of Medicine at Mount Sinai Department of Pediatrics
Cedars-Sinai Medical Center
Tracks
Related Products
Uncontrolled Therapeutic Observations in IBD
SOCIETY: AGA In this session, several clinically relevant presentations will put the attendee at the cutting edge of research and clinical care, with regard to stem cells for perinal fistulas, biologic de-escalation, subcutaneous biologics, and use of small molecules in microscopic colitis
Role of the Environment in IBD
SOCIETY: AGA As our scientific tools improve, so does our ability to link the environment with different aspects of IBD…
Novel Observations in IBD
MONITORING IBD BY INTESTINAL ULTRASOUND DECREASES TIME TO TREATMENT CHANGE AND TIME TO REMISSION IN COMPARISON TO CONVENTIONAL MANAGEMENT: ANALYSIS OF PATIENTS WITH IBD ON MULTIPLE IBD THERAPIES
IBD Controlled Trials II
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…
